Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010; 36 Suppl 2:S3-18.Frid A Hirsch L,Gaspar R. New injection recomm endations for patients with diabetes[J].Diabetes & metabolism 2010,...
Materials engineers atStanford Universityhave developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro, Trulicity, Victoza, and others to just once every four months. In a new study, published Nov. ...
FDA approves tirzepatide: A potent new drug for type 2 diabetes 图片上传失败 重试 The Food and Drug Administration (FDA) has approved a novel first-in-class drug to treat type 2 diabetes. The drug is called tirzepatide. A person has it as a once-weekly injection under the skin. I...
Europe is slightly ahead of the game when it comes to incorporating patient-reported outcomes into the diabetes drug approval pathway, as the EMA approved the first patient-reported outcome label claim for a diabetes drug last year. Following a phase III trial of once-weekly injection of Lilly'...
Significant Weight Loss and Reduced Diabetes Risk In STEP1, 1,961 participants with overweight or obesity received a weekly injection of 2.4 mg of semaglutide or a placebo for 68 weeks. STEP4 involved 803 participants with overweight or obesity. All received weekly injections of 2.4mg semaglutide...
Long- acting forms of once-weekly injection, such as exenatide LAR, are under development. When used in combination with metformin, sulfonylureas, TZDs, or metformin plus a sulfonylurea, exenatide has been shown to result in weight loss [142]. Daily liraglutide therapy had similar effects with ...
Medications for diabetes comprise either GLP-1 receptor agonists, with short (one or two daily injections: Exenatide, Liraglutide, Lixisenatide) or long duration (one injection once weekly: extended-released Exenatide, Albiglutide, Dulaglutide, Taspoglutide); or oral compounds inhibiting dipeptidyl peptid...
64 Currently, high-dose rifapentine in combination with other drugs is undergoing Phase II clinical trials for the treatment of drug-susceptible TB. Results showed that a 6 month regimen that included weekly administration of high-dose rifapentine and moxifloxacin was as effective as the control ...
first Glucagon-like peptide-1 (GLP-1) receptor agonist weekly preparation Bydureon® (generic name Exenatide Microsphere for injection) has been formally approved by China Food and Drug Administration (CFDA), as a new treatment option to improve glycemic control for patients with type 2 diabetes....
Avalglucosidase alfa therapy for Pompe disease is diluted in dextrose 5% solution in water (D5W) for infusion, which raises questions about the potential for hyperglycemia or worsening diabetes. Using United States insurance claims data, we assessed the impact of biweekly infusions on hyperglycemia,...